Zevra Therapeutics' Upcoming Conference Participation
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is a dynamic company dedicated to addressing the critical needs of individuals suffering from rare diseases. With a focus on innovation and patient care, Zevra has planned meaningful engagements at future investor conferences. Neil F. McFarlane, the company's President and CEO, will be representing Zevra at these important events.
Key Events on the Horizon
The upcoming conferences will create vital opportunities for Zevra to connect with the investment community. The first major event is the Piper Sandler 36th Annual Healthcare Conference, scheduled for December 4. This forum aims to foster discussions around the challenges and advancements in healthcare, particularly for rare diseases. Zevra's participation is set for 10:30 a.m. ET, showcasing their commitment to transparency and collaboration.
Innovative Presentations at Oppenheimer Summit
Following the Piper Sandler event, Zevra Therapeutics will also take part in the Oppenheimer Movers in Rare Disease Summit. This exclusive event will take place on December 12 and will feature elevator pitches from companies working on transformative solutions for rare diseases. Zevra is excited to outline its strategic goals during this session, which starts at 2:45 p.m. ET.
One-on-One Meetings for Attendees
During both conferences, Zevra's management team will be available for individualized meetings with investors and other interested parties who have registered for the events. This approach allows for deeper conversations about Zevra's initiatives and future directions in the rare disease landscape.
Live Webcast and Access to Information
For those unable to attend in person, a live webcast of the Piper Sandler discussion will be available. The webcast will be accessible on the Investor Relations section of Zevra's official website, ensuring that all stakeholders have the opportunity to engage with the company's narrative.
About Zevra Therapeutics, Inc.
Zevra Therapeutics stands firm in its mission to combine innovative science with patient-focused strategies to develop transformational therapies for rare diseases. The company employs unique data-driven approaches to navigate the challenges typical in drug development. Zevra aims to introduce life-changing treatments to help those with limited or no treatment options available.
For those seeking more information about Zevra's endeavors in the rare disease sector, the company maintains a comprehensive online presence. Their website offers insights, updates, and resources pertinent to current and prospective investors. You can also connect with Zevra on various social media platforms such as X and LinkedIn, enriching the dialogue surrounding rare disease treatment.
Contact Information for Zevra Therapeutics
For inquiries, you can reach out to Nichol Ochsner at +1 (732) 754-2545 or via email at nochsner@zevra.com. In addition, for public relations-related queries, David Schull can be contacted at +1 (858) 717-2310 or at david.schull@russopartnersllc.com.
Frequently Asked Questions
What is Zevra Therapeutics, Inc. focused on?
Zevra Therapeutics is focused on creating innovative treatments for rare diseases with unmet medical needs.
When are the upcoming conferences Zevra is participating in?
Zevra will participate in the Piper Sandler Conference on December 4 and the Oppenheimer Summit on December 12.
How can investors access the live webcast?
The live webcast of the Piper Sandler discussion will be available in the Investor Relations section of Zevra's website.
Who can I contact for more information about Zevra?
For more information, you can contact Nichol Ochsner at +1 (732) 754-2545 or reach out via email.
What mission does Zevra Therapeutics uphold?
Zevra is dedicated to developing transformative therapies aimed at improving the lives of individuals living with rare diseases.
